GLP-1 Drugs and Cancer: Which Cancer Subtypes May Benefit Most?

By Editorial Team

Interest in GLP-1 receptor agonists (GLP-1 RAs) such as Semaglutide, Tirzepatide, and Liraglutide has expanded far beyond diabetes and weight loss.

Researchers are now exploring how these metabolic therapies may influence:

  • cancer prevention,

  • obesity-related cancer risk,

  • tumor metabolism,

  • inflammation,

  • insulin signaling,

  • and even response to immunotherapy.

While GLP-1 drugs are not approved cancer treatments, mounting evidence suggests they may play a role in the future of metabolic precision oncology — particularly in cancers strongly linked to obesity, insulin resistance, and chronic inflammation.

What Are GLP-1 Drugs?

GLP-1 receptor agonists are medications originally developed for:

  • type 2 diabetes,

  • obesity,

  • and metabolic disease.

They work by:

  • improving insulin sensitivity,

  • reducing appetite,

  • slowing gastric emptying,

  • lowering blood glucose,

  • and promoting substantial weight loss.

Popular examples include:

  • Ozempic

  • Wegovy

  • Mounjaro

  • Zepbound

  • Saxenda

Their cancer relevance stems from the growing understanding that:

obesity and metabolic dysfunction are major drivers of many cancers.

Why Metabolism Matters in Cancer

Many tumors depend on:

  • glucose,

  • insulin,

  • IGF-1 signaling,

  • inflammatory cytokines,

  • and altered lipid metabolism.

Obesity can create a tumor-promoting environment through:

  • hyperinsulinemia,

  • chronic inflammation,

  • increased estrogen production,

  • adipokine imbalance,

  • and immune dysfunction.

GLP-1 therapies may help modify several of these pathways simultaneously.

Researchers are particularly interested in whether metabolic interventions could:

  • reduce cancer risk,

  • improve treatment response,

  • lower recurrence risk,

  • and enhance survivorship outcomes.

Cancer Subtypes Potentially Most Relevant to GLP-1 Therapy

1. ER-Positive Breast Cancer

Among the strongest areas of interest.

Especially:

  • postmenopausal breast cancer,

  • estrogen receptor-positive (ER+) disease,

  • obesity-associated breast cancer.

Obesity increases:

  • estrogen production from adipose tissue,

  • insulin signaling,

  • inflammatory cytokines,

  • and recurrence risk.

Potential mechanisms by which GLP-1 drugs may help include:

  • weight reduction,

  • insulin lowering,

  • improved metabolic health,

  • decreased inflammatory signaling.

Researchers are also exploring metabolic optimization alongside:

  • endocrine therapy,

  • CDK4/6 inhibitors,

  • targeted therapies.

2. Colorectal Cancer

Colorectal cancer has strong links to:

  • obesity,

  • visceral fat,

  • insulin resistance,

  • metabolic syndrome,

  • and type 2 diabetes.

Potentially relevant tumor biology includes:

  • PI3K-AKT-mTOR activation,

  • glucose-dependent metabolism,

  • inflammatory microenvironments.

Scientists are studying whether GLP-1-mediated metabolic improvement could influence:

  • cancer risk,

  • recurrence,

  • and treatment outcomes.

There is also increasing interest in:

  • microbiome interactions,

  • gut hormone signaling,

  • and metabolic immunology.

3. Liver Cancer (Hepatocellular Carcinoma)

One of the most promising future applications.

Especially relevant for:

  • MASLD-associated liver cancer,

  • NASH-related liver cancer,

  • obesity-driven liver disease.

As metabolic liver disease becomes a leading cause of liver cancer worldwide, therapies that improve:

  • fatty liver disease,

  • insulin resistance,

  • inflammation,

  • and fibrosis
    could become increasingly important.

GLP-1 drugs have already shown substantial promise in:

  • reducing liver fat,

  • improving metabolic markers,

  • and potentially slowing liver disease progression.

4. Endometrial Cancer

Endometrial cancer is one of the cancers most strongly associated with obesity.

Potentially relevant mechanisms include:

  • estrogen excess,

  • insulin resistance,

  • chronic inflammation,

  • PI3K pathway activation.

Weight loss and metabolic improvement may help:

  • reduce risk,

  • improve hormonal balance,

  • and lower inflammatory signaling.

This area is receiving growing attention in women’s metabolic oncology research.

5. Pancreatic Cancer

Pancreatic cancer remains highly aggressive and biologically complex.

Potential relevance of GLP-1 therapy includes:

  • obesity reduction,

  • improved insulin sensitivity,

  • metabolic risk reduction.

However, GLP-1 drugs are not established pancreatic cancer treatments.

Research currently focuses more on:

  • prevention,

  • metabolic risk modification,

  • and systemic metabolic health.

Because pancreatic cancer often causes severe weight loss and cachexia, clinical use requires careful consideration.

6. Prostate Cancer

Interest is increasing in:

  • obesity-associated aggressive prostate cancer,

  • insulin-resistant patients,

  • metabolic complications during androgen deprivation therapy (ADT).

GLP-1 therapies may potentially help improve:

  • cardiovascular risk,

  • metabolic syndrome,

  • visceral adiposity,

  • insulin resistance.

Direct anti-tumor effects remain uncertain.

Could GLP-1 Drugs Enhance Immunotherapy?

One emerging area of research involves the intersection between:

  • metabolism,

  • obesity,

  • inflammation,

  • and immune response.

Scientists are investigating whether metabolic optimization may improve:

  • T-cell function,

  • tumor microenvironment balance,

  • immune checkpoint response,

  • systemic inflammation.

This has led to growing interest in combining:

  • metabolic therapy,

  • immunotherapy,

  • ketogenic strategies,

  • exercise,

  • and precision nutrition.

The field remains early-stage but rapidly evolving.

Precision Oncology and “Metabolic Subtyping”

Future oncology may increasingly classify cancers not just by:

  • organ type,

  • or DNA mutations,

but also by:

  • metabolic phenotype,

  • insulin dependence,

  • inflammatory status,

  • and immune environment.

Researchers are exploring biomarkers such as:

  • fasting insulin,

  • HOMA-IR,

  • visceral adiposity,

  • metabolic transcriptomics,

  • PI3K pathway activation,

  • inflammatory cytokines.

This could eventually help identify:

which patients may benefit most from metabolic interventions such as GLP-1 therapy.

Are GLP-1 Drugs Cancer Treatments?

At present:

  • GLP-1 drugs are not approved cancer therapies,

  • evidence for direct anti-cancer activity remains limited,

  • and they should not replace standard oncology treatment.

However, evidence is growing that these therapies may influence:

  • cancer risk,

  • obesity-related cancer biology,

  • survivorship health,

  • metabolic dysfunction,

  • and systemic inflammation.

Their future role may be as part of:

  • integrative oncology,

  • supportive metabolic care,

  • and precision prevention strategies.

The Future: Integrative Precision Metabolic Oncology

The next generation of cancer care may combine:

  • genomic profiling,

  • metabolic optimization,

  • immunotherapy,

  • targeted therapies,

  • microbiome science,

  • lifestyle medicine,

  • and AI-driven personalization.

In this emerging framework, GLP-1 therapies may become one component of a broader systems-based approach aimed at:

  • reducing metabolic drivers of cancer,

  • improving treatment resilience,

  • and personalizing supportive care.

The future of oncology may not be about a single “miracle drug,” but rather:

intelligently combining metabolic, immune, genomic, and lifestyle interventions for each individual patient.

Related Topics

  • Precision Oncology and AI

  • Metabolic Therapy for Cancer

  • Ketogenic Diet and Cancer

  • Insulin Resistance and Tumor Growth

  • Obesity-Associated Cancers

  • Nutrigenomics and Precision Nutrition

  • Repurposed Drugs in Oncology

  • Immunometabolism and Cancer

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiation. Access to modern cancer care also remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings may face significant barriers to timely diagnosis and access to cutting-edge treatments. In this context, repurposed drugs—including ivermectin—are sometimes discussed in research and public discourse due to their low c...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146 (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer ( J Clin Oncol 2025 ) Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balsti...
Read more

Archive

Show more